These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21748440)

  • 1. Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.
    Wang Y; Li JQ; Shao C; Shi CH; Liu F; Yang ZY; Qiu JX; Li YM; Fu Q; Zhang W; Xue W; Lei YH; Gao JY; Wang JY; Gao XP; Yuan JL; Bao TY; Zhang YT
    Ir J Med Sci; 2011 Dec; 180(4):865-72. PubMed ID: 21748440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
    Hu YC; Yeh S; Yeh SD; Sampson ER; Huang J; Li P; Hsu CL; Ting HJ; Lin HK; Wang L; Kim E; Ni J; Chang C
    J Biol Chem; 2004 Aug; 279(32):33438-46. PubMed ID: 15166229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells.
    Rahman MM; Miyamoto H; Takatera H; Yeh S; Altuwaijri S; Chang C
    J Biol Chem; 2003 May; 278(22):19619-26. PubMed ID: 12649293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
    Yeh S; Kang HY; Miyamoto H; Nishimura K; Chang HC; Ting HJ; Rahman M; Lin HK; Fujimoto N; Hu YC; Mizokami A; Huang KE; Chang C
    Endocrine; 1999 Oct; 11(2):195-202. PubMed ID: 10709768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
    Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
    PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
    Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
    Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
    Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
    Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
    J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and function of androgen receptor coactivators in prostate cancer.
    Culig Z; Comuzzi B; Steiner H; Bartsch G; Hobisch A
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):265-71. PubMed ID: 15663989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform.
    Alen P; Claessens F; Schoenmakers E; Swinnen JV; Verhoeven G; Rombauts W; Peeters B
    Mol Endocrinol; 1999 Jan; 13(1):117-28. PubMed ID: 9892017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
    Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different expression of androgen receptor coactivators in human prostate.
    Fujimoto N; Mizokami A; Harada S; Matsumoto T
    Urology; 2001 Aug; 58(2):289-94. PubMed ID: 11489729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.
    Ravenna L; Lubrano C; Di Silverio F; Vacca A; Felli MP; Maroder M; D'Eramo G; Sciarra F; Frati L; Gulino A
    Prostate; 1995 Jun; 26(6):290-8. PubMed ID: 7784269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
    Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
    J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.